Company Introduction

LumiSTAR Biotechnology is an expert in designs of a range of optical platforms for cellular dynamics measurements. Our expertise includes induced pluripotent stem cell (iPSC) technology, regenerative medicine, optogenetic tools, and indicator design. All of these technologies are packaged into an all-optical platform for phenotypic screening, drug discovery and toxicity testing. This high content platform enables customers to do their drug screening tasks in a more efficient and economical way (96 or 384 well formats). We offer a variety of functional assays for different disease modeling; customization service is also available.

Brief description of main products or services 

COVID-19 High Throughput Neutralizing Screening Platform:
LumiSTAR offers a range of mutant strains of pseudovirus for high throughput neutralizing screening, which can evaluate antibodies or drugs that inhibit virus entry through the competitive binding with ACE2 receptor. This platform contains imaging-based analysis to count viral entry efficiency, which can provide more solid evidence for users.

COVID-19 Neutralizing Antibody Quantification Kit for in vitro use:
ELISA based products to support 96 well high throughput testing. This product can be used in vaccine developments and validations. Moreover, in the post COVID-19 pandemic era, the kit can be used to provide service for evaluating anti COVID-19 protectivity after vaccination for individuals. 

High Content/Throughput Phenotypic Drug Screening Platform:
In LumiSTAR’s platform, we offer various optical protein-based reporters with different detection dynamic ranges against cellular physiology. By incorporation with iPSC or disease-model cell lines, real-time monitoring how the cellular physiology influenced by testing drugs can be achieved. Moreover, our protein-based reporters, compared with chemical dyes, are non-toxic to the cells, and thus long-term observations can be carried out. This platform can be applied in big library screening, drug repurposing, cardiac toxicity evaluation (using iPSC-derived human cardiomyocytes) and precision medicine.